

## Zenlabs Ethica Ltd.

CIN NO.: L74900CH1993PLC033112, GSTIN NO.: 03AAFCS6226G1ZL

Regd. Office: Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel.: 0172-465 1105, Fax: 0172-265 6855

E-mail: queries@zenlabsethica.com, Website: www.zenlabsethica.com

The Manager
Department of Corporate Services **BSE Limited**Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001
Maharashtra

Date: 07.02.2025

Subject: Outcome of Board Meeting -Un-Audited Financial Results of the Company for the Quarter and Nine months ended 31.12.2024.

Ref: Zenlabs Ethica Limited (Scrip Code: 530697).

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today on Friday, February 07, 2025 at 2:00 P.M and Concluded at 3:30 P.M., inter alia, approved the following:

- 1. The Unaudited Financial Results for the quarter and nine months ended on 31st December, 2024. We are enclosing herewith the following documents in this respect:
  - a. Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2024.
  - b. Limited Review Report on the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2024 issued by M/s N Kumar Chhabra and Co., Statutory Auditors of the Company.

The aforesaid documents are also being disseminated on company's website at www.zenlabsethica.com.

You are requested to take the above mentioned information on your records.

Thanking You

Yours Truly
For ZENLABS ETHICA LIMITED

Manju Bala Company Secretary & Compliance Officer M. No. ACS 67831

#### ZENLABS ETHICA LIMITED

### Corporate Identification Number L74900CH1993PLC033112, GSTIN 03AAFCS6226G1ZL Registered Office Plot No. 194-195, 3<sup>rd</sup> Floor, Industrial Area, Phase II, Chandigarh - 160 002 Telephone 0172-465 1105, Fax: 0172-265 6855



E-mail: queries@zenlabsethica.com, Website: www.zenlabsethica.com

Statement of unaudited financial results for the quarter and nine months ended 31st December, 2024							
	Particulars	(₹ in Lakhs except EPS data)					
Sr. No.		Quarter Ended			Nine Months ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	Revenue from operations	1,272.29	1,335.15	1,559.95	3,843.71	4,323.59	5,856.31
2.	Other Income	0.25	0.13	0.40	0.67	27.63	29.92
3.	Total Income (1+2)	1,272.55	1,335.28	1,560.35	3,844.37	4,351.22	5,886.23
4.	Expenditure						
	a) Purchase of stock in trade	915.31	1,127.50	1,357.53	3,027.69	3,436.09	4,441.41
	b) (Increase)/decrease in stock-in-trade	24.57	(119.82)	(193.22)	(175.68)	(166.45)	(62.64)
	c) Employees benefit expenses	102.35	102.52	118.49	316.96	334.31	445.75
	d) Finance costs	24.15	22.86	22.06	69.84	58.61	83.37
	e) Depreciation and Amortisation	31.54	31.43	32.29	94.88	96.88	129.44
	f) Other Expenditure	162.09	163.21	208.13	483.39	554.49	790.75
	Total Expenses	1,260.01	1,327.70	1,545.28	3,817.08	4,313.93	5,828.08
5.	Profit before Exceptional & Extraordinary Items (3-4)	12.54	7.59	15.07	27.29	37.29	58.15
6.	Exceptional Items	-	-		-	-	-
7.	Profit Before Tax (5-6)	12.54	7.59	15.07	27.29	37.29	58.15
8.	Tax Expenses						
	a) Current Tax	4.07	2.32	4.03	8.39	10.33	20.59
	b) Deferred Tax	(0.04)	0.10	(0.37)	1.04	0.10	(4.56)
9.	Profit(+)/ Loss(-) for the period (7-8)	8.51	5.17	11.41	17.86	26.86	42.12
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Re-measurement of the net defined benefit plans	(1.31)	4.66	0.55	4.95	(0.53)	(0.23)
	Tax on above	0.33	(1.17)	(0.14)	(1.25)	0.13	0.06
11.	Total Other comprehensive Income, net of tax	(0.98)	3.49	0.41	3.70	(0.40)	(0.17)
	-						
12.	Total comprehensive Income for the period	7.53	8.66	11.82	21.56	26.46	41.95
13.	Paid up equity share capital	651.00	651.00	651.00	651.00	651.00	651.00
	(Face Value of ₹ 10/- each per share)						
14.	Earnings Per Share (Not Annualised)						
	-Basic (in ₹)	0.13	0.08	0.18	0.27	0.41	0.65
	-Diluted (in ₹)	0.13	0.08	0.18	0.27	0.41	0.65

#### **NOTES:**

- 1. The above financial results for the quarter and nine months ended 31<sup>st</sup> December, 2024 have been reviewed by the Audit Committee and were approved and taken on record by the Board of Directors in their respective meeting held on 7<sup>th</sup> February, 2025. The statutory auditors of the Company have expressed an unmodified opinion in limited review report on these financial results.
- 2. The Standalone financial results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- 3. The Company is considered to be a single segment company engaged in the trading of pharmaceuticals formulation. Consequently, the Company has, in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 "Operating Segment".
- 4. As on 31<sup>st</sup> December, 2024, the Company does not have any subsidiary/ associate/ joint venture company.
- 5. Previous period figures have been re-grouped/ re-classified, wherever necessary, to conform to current period's classifications.

By order of Board for Zenlabs Ethica Limited

Sanjay Dhir Place: Chandigarh

Date: 7<sup>th</sup> February, 2025

Whole Time Director

# N. KUMAR CHHABRA AND CO. CHARTERED ACCOUNTANTS

# 1081, SECTOR 27 B, CHANDIGARH – 160 019 PH: + 91 172 5088800

e-mail: info@nkumarca.com

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Financial Results of Zenlabs Ethica Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

#### The Board of Directors Zenlabs Ethica Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of **Zenlabs Ethica Limited** ("the Company") for the quarter ended 31<sup>st</sup> December, 2024 and the year to date results for the period 1<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.
- 2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under Section 133 of Companies Act, 2013 (the 'Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in an Audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and

other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### for N Kumar Chhabra and Co.

Chartered Accountants ICAI Firm's registration Number 00837N

ASHISH Digitally signed by ASHISH CHHABRA Date: 2025.02.07 15:21:08 +05'30'

CA. Ashish Chhabra

*Partner* 

Membership Number 507083 **UDIN:** 25507083BMKNDS5111

Place: Chandigarh

**Date:** 7th February 2025